Table 1.
Patient characteristics
| Characteristic | |
|---|---|
| Age, years | |
| Median (Range) | 55 (25–78) |
| Race | |
| White | 13 (50%) |
| Black | 11 (42.3%) |
| Asian | 1 (3.8%) |
| Other | 1 (3.8%) |
| ECOG | |
| 0 | 12 (46.2%) |
| 1 | 11 (42.3%) |
| 2 | 3 (11.5%) |
| BRCA status (germline) | |
| BRCA1/2 positive | 1 (3.8%) |
| BRCA negative | 15 (57.7%) |
| Unknown/Not Done | 10 (38.5%) |
| Prior (neo)adjuvant chemotherapy | |
| Yes | 24 |
| Anthracycline and taxane based | 16 |
| Anthracycline based | 2 |
| Taxane based | 5 |
| Other/unspecified | 2 |
| No | 2 |
| Prior (neo)adjuvant hormonal therapy* | 5 |
| Other | 1 |
| No. prior systemic therapy for metastatic disease | |
| All regimens - Median (Range) | 1.5 (0–4) |
| Chemotherapy | 1 (0–4) |
| Hormonal* | 1.5 (1–2) |
| Other/unknown | 1 clinical trial 1 PDL-1 trial |
| AR status (N=21) | |
| Positive | 5 (23.8%) |
| Negative | 16 (76.2%) |
*
Eligible patients could have previously had ER-positive and/or HER2-positive disease, but must have had confirmation of TNBC on their most recent tissue biopsy.